What is NOEM's issuance of warrants to purchase common stock?

NOEM (NOEM) reported issuance of warrants to purchase common stock of $51.75K in Q4 2024.

What does issuance of warrants to purchase common stock mean?

The value assigned to warrants issued to purchase common stock, recorded as an adjustment to additional paid-in capital. This metric captures the non-cash equity component of financing arrangements, often used as an incentive for investors. It highlights the potential future dilution and the cost of capital associated with derivative instruments.

NOEM NOEM Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Ispire Technology Inc.ISPR

$91.49K—

Envoy MedicalCOCH

$882K+348%

CO2 Energy Transition Corp. Common StockNOEM

$51.75K—

Oruka Therapeutics, Inc.ORKA

$2.52M-75.7%

ADMA BiologicsADMA

$1.4M—

Evommune EVMN

$150—

Other financials

Income statement

See full

Operating income-$196.7K-15.2%

Net income$309.2K-23.9%

EPS (diluted)-$0.01—

Balance sheet

See full

Cash & equivalents$26.1K-95.9%

Total debt$11.7K—

Total equity-$2.0M-33.3%

Total assets$72.1M+1.7%

Cash flow

See full

Operating cash flow-$1.1M-237%

Valuation

See full

Market cap$100.08M+3.5%

P/E64.4×-47.0×

Returns & leverage

See full

Return on equity-90.8%—

Current ratio2.6×+0.7×

Where this comes from

Reported directly by NOEM in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: NOEM’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about NOEM's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NOEM's issuance of warrants to purchase common stock?: NOEM (NOEM) reported issuance of warrants to purchase common stock of $51.75K in Q4 2024.
What does issuance of warrants to purchase common stock mean?: The value assigned to warrants issued to purchase common stock, recorded as an adjustment to additional paid-in capital. This metric captures the non-cash equity component of financing arrangements, often used as an incentive for investors. It highlights the potential future dilution and the cost of capital associated with derivative instruments.